ArticlePrecision radiation oncology2026
Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive-stage small cell lung cancer.
Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We evaluated the effect of thoracic radiotherapy (TRT) on extensive-stage small-cell lung cancer (ES-SCLC) in elderly patients (aged ≥ 60 years) in the era of immunotherapy (IO) and analyzed the prognostic factors to guide personalized treatment. Methods: The clinical data of 178 elderly patients were reviewed. Kaplan-Meier curves were generated to estimate the survival rates. Multivariate prognostic analyses were performed using Cox proportional hazards models. Results: The mOS in the CRT-IO group was superior to that in the CT-IO group (22.0 vs. 14.7 months, Conclusions: CRT-IO should be prioritized as a treatment for elderly patients with ES-SCLC with good performance status and liver metastasis. However, CRT could be a viable option for patients with a compromised performance status or for whom economic factors are a concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.